Oramed Pharmaceuticals Ownership | Who Owns Oramed Pharmaceuticals?


OverviewForecastFinancialsChart

Oramed Pharmaceuticals Ownership Summary


Oramed Pharmaceuticals is owned by 11.15% institutional investors, 18.05% insiders, and 70.80% retail investors. Bml capital management is the largest institutional shareholder, holding 7.65% of ORMP shares. iShares Micro-Cap ETF is the top mutual fund, with 0.21% of its assets in Oramed Pharmaceuticals shares.

ORMP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockOramed Pharmaceuticals11.15%18.05%70.80%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.80%11.85%52.35%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bml capital management3.17M7.65%$10.77M
Mercer global advisors inc /adv1.91M4.61%$6.50M
Gem investment advisors1.64M3.96%$5.58M
Murchinson1.32M3.18%$4.47M
Boothbay fund management600.72K1.45%$2.04M
Marshall wace, llp259.61K0.63%$882.68K
Rathbones group233.02K0.56%$792.26K
Bank of america corp /de/173.24K0.43%$445.23K
Dimensional fund advisors lp158.21K0.38%$537.74K
Wells fargo & company/mn157.59K0.38%$535.79K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bml capital management3.17M6.91%$10.77M
Gem investment advisors1.64M5.48%$5.58M
Murchinson1.32M0.57%$4.47M
Sage capital management17.98K0.03%$61.13K
Boothbay fund management600.72K0.03%$2.04M
Catalyst funds management pty23.50K0.01%$79.90K
Glass jacobson investment advisors10.54K0.01%$35.84K
Mercer global advisors inc /adv1.91M0.01%$6.50M
Ritholtz wealth management155.48K0.01%$528.63K
Prelude capital management35.31K0.01%$120.06K

Top Buyers

HolderShares% AssetsChange
Mercer global advisors inc /adv1.91M0.01%1.91M
Ritholtz wealth management155.48K0.01%155.48K
O'shaughnessy asset management116.36K0.00%116.36K
Susquehanna group, llp136.22K0.00%110.23K
Hillsdale investment management97.30K0.01%97.30K

Top Sellers

HolderShares% AssetsChange
Gem investment advisors1.64M5.48%-358.73K
Two sigma advisers, lp---213.00K
Bank of america corp /de/173.24K--113.81K
Citadel advisors98.63K0.00%-97.39K
Peapod lane capital---84.78K

New Positions

HolderShares% AssetsChangeValue
Mercer global advisors inc /adv1.91M0.01%1.91M$6.50M
Ritholtz wealth management155.48K0.01%155.48K$528.63K
O'shaughnessy asset management116.36K0.00%116.36K$395.63K
Hillsdale investment management97.30K0.01%97.30K$330.82K
Hudson bay capital management lp51.67K0.00%51.67K$175.68K

Sold Out

HolderChange
Innealta capital-13.00
Mather group, llc.-100.00
Global retirement partners-100.00
Hopwood financial services-200.00
Beacon capital management-219.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202635-37.50%4,617,647-58.24%111.59%19-26.92%8-20.00%
Dec 31, 202535-25.53%6,592,201-28.42%153.24%14-12.50%6-25.00%
Sep 30, 202544-4.35%7,236,0761.46%175.70%1550.00%8-46.67%
Jun 30, 202548-11.11%7,251,754-6.69%174.91%11-42.11%15-16.67%
Mar 31, 202554-10.00%7,772,7871.30%195.40%21-8.70%16-5.88%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Micro-Cap ETF83.14K0.21%-
SPDR® Portfolio Developed Wld ex-US ETF56.82K0.14%-
RBC Microcap Value I45.30K0.11%-40.00K
Dimensional US Core Equity 2 ETF36.54K0.09%-
Bailard Micrcap Value32.48K0.08%32.48K
Bailard Small Cap Value32.48K0.08%32.48K
Nationwide Bailard Sm Cp Val M32.48K0.08%-
MTF TR TA-Growth29.23K0.07%-1.13K
Avantis US Small Cap Equity ETF28.16K0.07%-
Dimensional US Small Cap ETF26.90K0.07%-

Recent Insider Transactions


DateNameRoleActivityValue
Apr 03, 2023Mayer Arie-Buy$11.12K
Apr 04, 2023Mayer Arie-Buy$8.40K
Mar 16, 2023KIDRON NADAV President and CEOBuy$53.01K
Mar 14, 2023KIDRON NADAV President and CEOBuy$201.00K
Mar 14, 2023Kidron Miriam Chief Scientific OfficerSell$201.00K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4--
2025 Q2--
2025 Q1--
2024 Q4--

ORMP Ownership FAQ


Who Owns Oramed Pharmaceuticals?

Oramed Pharmaceuticals shareholders are primarily institutional investors at 11.15%, followed by 18.05% insiders and 70.80% retail investors. The average institutional ownership in Oramed Pharmaceuticals's industry, Biotech Stocks , is 35.80%, which Oramed Pharmaceuticals falls below.

Who owns the most shares of Oramed Pharmaceuticals?

Oramed Pharmaceuticals’s largest shareholders are Bml capital management (3.17M shares, 7.65%), Mercer global advisors inc /adv (1.91M shares, 4.61%), and Gem investment advisors (1.64M shares, 3.96%). Together, they hold 16.23% of Oramed Pharmaceuticals’s total shares outstanding.

Does Blackrock own Oramed Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Oramed Pharmaceuticals.

Who is Oramed Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Bml capital management is Oramed Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.91% of its assets in 3.17M Oramed Pharmaceuticals shares, valued at 10.77M$.

Who is the top mutual fund holder of Oramed Pharmaceuticals shares?

iShares Micro-Cap ETF is the top mutual fund holder of Oramed Pharmaceuticals shares, with 0.21% of its total shares outstanding invested in 83.14K Oramed Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools